Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
In patients with IV NSCLC and EGFR mutation, is there a cutoff on the % of allele frequency that is considered to be too low to be actionable?
Related Questions
Would you use consolidation immunotherapy after chemoradiation for patients with stage III NSCLC and EGFR amplification?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
How would you approach treatment for EGFR-mutant NSCLC with acquired ERBB2 mutation and amplification as resistance to prior osimertinib-based therapy?
Is there any antiresorptive therapy that you would be comfortable prescribing if the patient refuses to see a dentist for clearance and is at risk of skeletal-related events?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
Would you give consolidation durvalumab to a patient who underwent chemoradiation for his stage III NSCLC and is being started on antifibrotic therapy by pulmonology for his ILD?
What are your top takeaways in thoracic cancers from ESMO 2025?
For a patient with NSCLC harboring an EGFR or ALK mutation that transforms into SCLC, would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?
How would you approach adjuvant therapy for patients with mucinous lung adenocarcinoma with an intestinal phenotype?
What would your approach be to treatment in a patient with stage IV thymic squamous cell carcinoma who received neoadjuvant carboplatin, paclitaxel, and ramucirumab and underwent R1 resection?
